NUWELLIS INC NUWE 深 滬
已收盤 10-17 16:00:00 美东时间
3.44
+0.020
+0.58%
華盛通- 最 高3.455
- 今 開3.26
- 成交量 4.72万股
- 最 低 3.26
- 昨 收 3.42
- 總市值 310.53万
- 52周最高 175.98
- 市盈率 靜 --
- 換手率 5.23%
- 52周最低 3.09
- 委 比 58.49%
- 總股本 90.27万
- 歷史最高 2012724000.00
- 量 比 0.97
- 振 幅 5.70%
- 歷史最低 3.26
- 每 手 1
- 風險率 23.66%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Robert B. Scott Resigns As CFO Of Nuwellis; John L. Erb Appointed Interim CFO
https://www.sec.gov/Archives/edgar/data/1506492/000114036125037713/ef20056785_8k.htm
10-09 05:17
Nuwellis Announces ULTRA-Peds Registry Findings
Nuwellis ( ($NUWE) ) has provided an announcement. On September 30, 2025, Nuwel...
09-30 21:17
Nuwellis Announces Findings From ULTRA-Peds Registry Study Examining Real-World Use Of Aquadex System In Children With AKI, Fluid Overload, Or Congenital Kidney Failure
ULTRA-Peds Registry, the largest multi-center dataset of its kind, shows Aquadex therapy was well-tolerated in critically ill children, a population with extremely limited treatment optionsResults highlightULTRA-Peds Registry, the largest multi-center dataset of its kind, shows Aquadex therapy was well-tolerated in critically ill children, a population with extremely limited treatment options</
09-30 20:51
Nuwellis Announces 92% Survival in Children with Acute Kidney Injury (AKI), Fluid Overload or Congenital Kidney Failure Following Treatment with Aquadex®
The ULTRA-Peds registry, a multi-center observational study, shows Aquadex therapy is well-tolerated and effective in critically ill children with acute kidney injury, fluid overload, or congenital kidney failure. Findings include 92% patient survival, 66% survival to discharge, and 86% completion of intended treatment course. Results highlight the need for pediatric-specific devices like Vivian, Nuwellis’ CRRT system under development for neonat...
09-30 12:45
Nuwellis Receives New US Patent Reinforcing Vivian™ Pediatric Device Focused on Safer, More Precise Ultrafiltration
Nuwellis, Inc. has been granted U.S. Patent No. 12,415,021 for hemolysis sensing technology in extracorporeal blood filtration systems, aiding in detecting and localizing red blood cell destruction. This innovation supports their pediatric device, Vivian, and enhances safety in ultrafiltration therapy. Hemolysis, the breakdown of red blood cells, can pose serious risks, and existing detectors often fail to detect hemolyzed blood. The patent enabl...
09-18 13:00
Nuwellis, Inc. Participates in a Virtual Investor “What This Means” Segment
Nuwellis, Inc. (Nasdaq: NUWE) participated in a Virtual Investor "What This Means" segment, where Ryan Marthaler, Vice President of Product Marketing & Business Development, discussed the company's recent news. The National Institutes of Health (NIH) awarded a $3 million multi-year grant to Nuwellis' development partner, Koronis Biomedical Technologies Corporation (KBT). This grant will accelerate the development of Vivian™, Nuwellis’ pediatric c...
09-17 14:16
Nuwellis Secures NIH Grant for Pediatric Device Development
Nuwellis ( ($NUWE) ) has issued an update. On September 9, 2025, Nuwellis, Inc....
09-09 21:49
Nuwellis’ Vivian Receives $3 Million NIH Grant to Accelerate Pediatric Platform and Strengthen Fluid-Management Portfolio
Nuwellis Inc. announced it received a $3 million NIH grant to support the development of Vivian™, a pediatric CRRT device designed for patients weighing 2.5–20 kg. Currently, limited options exist for infants and small children with kidney failure, often requiring adult technologies adapted for their use. Vivian aims to address this gap with a pediatric-specific system featuring precise fluid management, integrated sensors for real-time monitorin...
09-09 13:00
Nuwellis Introduces New 24-Hour Aquadex™ Circuit to Support Hospital-Based Outpatient and Short-Term Fluid Management
Nuwellis, Inc. announced plans to launch a new 24-hour Aquadex therapy circuit in the U.S. this fall to support single-day outpatient sessions, complementing its existing 72-hour option for multi-day or inpatient care. This addition aims to help hospitals align Aquadex therapy with outpatient workflows, improve efficiency, and expand access for patients needing fluid removal without hospitalization. The 24-hour circuit supports predictable care s...
09-04 12:15
Nuwellis Announces At The Market Offering Agreement
Nuwellis ( ($NUWE) ) has shared an announcement. On September 3, 2025, Nuwellis...
09-03 21:19
